Benefit of standard versus low-dose tirofiban for percutaneous coronary intervention in very elderly patients with high-risk acute coronary syndrome.

MLA

Yun-ling LIN, et al. “Benefit of Standard versus Low-Dose Tirofiban for Percutaneous Coronary Intervention in Very Elderly Patients with High-Risk Acute Coronary Syndrome.” Acta Pharmacologica Sinica, vol. 30, no. 5, May 2009, pp. 553–58. EBSCOhost, https://doi.org/10.1038/aps.2009.38.

APA

Yun-ling LIN, Liang-long CHEN, Yu-kun LUO, Xing-chun ZHENG, & Wei-wei LI. (2009). Benefit of standard versus low-dose tirofiban for percutaneous coronary intervention in very elderly patients with high-risk acute coronary syndrome. Acta Pharmacologica Sinica, 30(5), 553–558. https://doi.org/10.1038/aps.2009.38

Chicago

Yun-ling LIN, Liang-long CHEN, Yu-kun LUO, Xing-chun ZHENG, and Wei-wei LI. 2009. “Benefit of Standard versus Low-Dose Tirofiban for Percutaneous Coronary Intervention in Very Elderly Patients with High-Risk Acute Coronary Syndrome.” Acta Pharmacologica Sinica 30 (5): 553–58. doi:10.1038/aps.2009.38.